Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto™ for the treatment of adult patients with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments.

See the Novartis announcement which includes PHEN President Thomas Farrington's comments about the impact of Pluvicto™ approval.

PHEN has been out front educating patients about PSMA. Watch its webinar: "PSMA, What It Is and Why It Matters to Prostate Cancer Patients".